Highly brain-permeable apoferritin nanocage with high dysprosium loading capacity as a new T2 contrast agent for ultra-high field magnetic resonance imaging

High sensitivity at ultra-high field (UHF) and sufficient potential to penetrate the brain are the most desirable characteristics in the development of contrast agents (CAs) for magnetic resonance imaging (MRI). However, incorporating such qualities into a single nanocarrier is challenging. Herein,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Biomaterials Ročník 243; s. 119939
Hlavní autoři: Kim, Hee-Kyung, Baek, Ah Rum, Choi, Garam, Lee, Jung-jin, Yang, Ji-ung, Jung, Hoesu, Lee, Taekwan, Kim, Dongkyu, Kim, Minsup, Cho, ArtE, Lee, Gang Ho, Chang, Yongmin
Médium: Journal Article
Jazyk:angličtina
Vydáno: Elsevier Ltd 01.06.2020
Témata:
Apoferritin
biocompatible materials
Brain
brain neoplasms
dysprosium
Dysprosium chelates
ferritin
ligands
magnetism
nanocarriers
Ultra-high field MRI
Brain
Apoferritin
Dysprosium chelates
Ultra-high field MRI
ISSN:0142-9612, 1878-5905, 1878-5905
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:High sensitivity at ultra-high field (UHF) and sufficient potential to penetrate the brain are the most desirable characteristics in the development of contrast agents (CAs) for magnetic resonance imaging (MRI). However, incorporating such qualities into a single nanocarrier is challenging. Herein, we report a new strategy for a highly brain-permeable MR CA with high sensitivity at UHF by loading dysprosium chelates (DyL) in apoferritin cavities (Apo-DyL). We also design the chelate ligand structure to increase DyL loading capacity within the apoferritin cavity. Using the intracerebroventricular (ICV) injection approach as a new delivery route for Apo-DyL, we demonstrate that apoferritin loaded with DyL can penetrate the brain–ventricular barrier and diffuse into the brain. This brain-permeable capability is unique to Apo-DyL, compared with other types of nanoparticles used in MRI. Apo-DyL also shows significant increase in MR sensitivity of DyL at UHF. Furthermore, based on brain tumor imaging at UHF, Apo-DyL can significantly enhance the tumor for a lower dose of the CA than the previously reported Gd- or Mn-loaded apoferritin nanoplatform. Therefore, Apo-DyL can be a novel nanoplatform that is a highly sensitive and versatile MR CA for UHF brain imaging.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0142-9612
1878-5905
1878-5905
DOI:10.1016/j.biomaterials.2020.119939